BCR-ABL/ABL RATIO INCREASE THAT CORRESPONDS TOPRESENCEOFBCR-ABL MUTATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY IMATINIB

被引：0
|
作者：
Tsaur, G. [1 ]
Ivanova, A. [1 ]
Popov, A. [1 ]
Yakovleva, Y. [1 ]
Riger, T. [1 ]
Ivanets, Y. [2 ]
Misyurin, A. [3 ]
Suchkova, M. [3 ]
Shorikov, E. [1 ]
Saveliev, L. [4 ]
Fechina, L. [1 ]
机构：
[1] Reg Childrens Hosp, Res Inst Med Cell Technol, Pediat Oncol & Hematol Ctr, Ekaterinburg, Russia
[2] Novartis Pharmaceut, BU Oncol, Ekaterinburg, Russia
[3] Minist Publ Hlth Russia, Hematol Res Ctr, Lab Gene Engn, Moscow, Russia
[4] Ural State Med Acad, Chair Lab Med, Ekaterinburg, Russia
来源：
CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2011年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [1] Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib
    Tsaur, Grigory
    Ivanova, Anna
    Popov, Alexander
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Misyurin, Andrey
    Suchkova, Marina
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    BLOOD, 2010, 116 (21) : 1402 - 1402
  • [2] Increase of BCR-ABL/ABL Ratio That Corresponds to BCR-ABL Mutation Detection In Chronic Myeloid Leukemia (CML) Patients Treated by Imatinib (IM)
    Tsaur, Grigory
    Popov, Alexander
    Ivanova, Anna
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    FASEB JOURNAL, 2011, 25
  • [3] THE CORRELATION BETWEEN THE MEDIUM ERYTHROCITARY VOLUME AND THE BCR-ABL/ABL RATIO IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Mihaila, R. G.
    Catana, A.
    Rezi, E.
    Mitea, S.
    Mihaila, R. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 546 - 547
  • [4] Clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Nicolini, Franck
    HEMATOLOGIE, 2006, 12 (06): : 373 - 374
  • [5] The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
    Wang, LH
    Knight, K
    Lucas, C
    Clark, RE
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 235 - 239
  • [6] BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib
    Gadzicki, D
    von Neuhoff, N
    Steinemann, D
    Just, M
    Büsche, G
    Kreipe, H
    Wilkens, L
    Schlegelberger, B
    CANCER GENETICS AND CYTOGENETICS, 2005, 159 (02) : 164 - 167
  • [7] Molecular breakpoint of BCR-ABL in chronic myeloid leukemia and imatinib response
    不详
    PHARMACOGENOMICS, 2010, 11 (09) : 1202 - 1203
  • [8] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
    Carella, Angelo Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
  • [9] BCR-ABL Mutations in Chronic Myeloid Leukemia
    Ernst, Thomas
    La Rosee, Paul
    Mueller, Martin C.
    Hochhaus, Andreas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (05) : 997 - +
  • [10] BCR-ABL IN CHRONIC MYELOID-LEUKEMIA
    不详
    LANCET, 1986, 2 (8501): : 258 - 259
12345